These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9250572)

  • 1. Dihydropyrimidine dehydrogenase deficiency: a potential etiology for 5-fluorouracil-induced neurotoxicity.
    Risso ME; Hasson NK; Lum BL
    Pharmacotherapy; 1997; 17(4):847-8; discussion 849. PubMed ID: 9250572
    [No Abstract]   [Full Text] [Related]  

  • 2. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.
    Diasio RB; Johnson MR
    Clin Cancer Res; 1999 Oct; 5(10):2672-3. PubMed ID: 10537327
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta.
    Beuzeboc P; Pierga JY; Stoppa-Lyonnet D; Etienne MC; Milano G; Pouillart P
    Eur J Cancer; 1996 Feb; 32A(2):369-70. PubMed ID: 8664058
    [No Abstract]   [Full Text] [Related]  

  • 4. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity.
    Milano G; Etienne MC; Pierrefite V; Barberi-Heyob M; Deporte-Fety R; Renée N
    Br J Cancer; 1999 Feb; 79(3-4):627-30. PubMed ID: 10027340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
    Kobayashi K; Sumi S; Kidouchi K; Mizuno I; Mohri N; Fukui T; Akamo Y; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1217-9. PubMed ID: 9679586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil.
    Johnson MR; Hageboutros A; Wang K; High L; Smith JB; Diasio RB
    Clin Cancer Res; 1999 Aug; 5(8):2006-11. PubMed ID: 10473079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency.
    Franco DA; Greenberg HS
    Neurology; 2001 Jan; 56(1):110-2. PubMed ID: 11148247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Mutations in the dihydropyrimidine dehydrogenase gene and their role in 5-fluororuracil intolerance].
    Gross E; Seck K; Kiechle M
    Zentralbl Gynakol; 2002 Dec; 124(12):574-9. PubMed ID: 12822071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question.
    van Kuilenburg AB
    Cancer Invest; 2006 Mar; 24(2):215-7. PubMed ID: 16537192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of dihydropyrimidine dehydrogenase on 5-fluorouracil treatment in cancer patients.
    Schneider HB; Becker H
    Eur J Med Res; 2003 May; 8(5):226-8. PubMed ID: 12844478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
    Innocenti F; Ratain MJ
    Clin Cancer Res; 2002 May; 8(5):1314; author reply 1315-6. PubMed ID: 12006555
    [No Abstract]   [Full Text] [Related]  

  • 12. [Neurotoxicity of 5-fluorouracil].
    Sucker C; Lambers C; Stockschläder M; Dölken G
    Dtsch Med Wochenschr; 2002 Sep; 127(39):2011-4. PubMed ID: 12324882
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity.
    Kouwaki M; Hamajima N; Sumi S; Nonaka M; Sasaki M; Dobashi K; Kidouchi K; Togari H; Wada Y
    Clin Cancer Res; 1998 Dec; 4(12):2999-3004. PubMed ID: 9865912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
    van Kuilenburg AB
    Eur J Cancer; 2004 May; 40(7):939-50. PubMed ID: 15093568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency].
    Beuzeboc P; Pierga JY; Lyonnet DS; Couturier J; Pouillart P
    Bull Cancer; 1996 Apr; 83(4):324-7. PubMed ID: 8680084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Detection of DPD-exon-14 skipping before 5-fluorouracil treatment?].
    Kliche KO
    Dtsch Med Wochenschr; 2002 Mar; 127(9):463-4. PubMed ID: 11870563
    [No Abstract]   [Full Text] [Related]  

  • 17. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
    Stéphan F; Etienne MC; Wallays C; Milano G; Clergue F
    Am J Med; 1995 Dec; 99(6):685-8. PubMed ID: 7503095
    [No Abstract]   [Full Text] [Related]  

  • 18. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.
    Boisdron-Celle M; Remaud G; Traore S; Poirier AL; Gamelin L; Morel A; Gamelin E
    Cancer Lett; 2007 May; 249(2):271-82. PubMed ID: 17064846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil.
    Johnson MR; Diasio RB
    Adv Enzyme Regul; 2001; 41():151-7. PubMed ID: 11384742
    [No Abstract]   [Full Text] [Related]  

  • 20. Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
    Deenen MJ; Beijnen JH; Schellens JH
    J Clin Oncol; 2008 Oct; 26(30):4997-8; author reply 4998-9. PubMed ID: 18809598
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.